Pfizer’s Lyme vaccine showed 73% efficacy, but missed a statistical hurdle. What comes next?
Pfizer will present 57 infectious disease abstracts at IDWeek 2026, including Phase 3 Lyme vaccine findings, new pediatric pneumococcal data and real-world RSV effectiveness studies. The programme highlights pipeline progress while leaving important regulatory and clinical questions unresolved.
